IP Library Granted Patent US 7,863,453
Granted Patent B2
US 7,863,453 · App. 12/391,049 · Granted Jan 4, 2011

Tartrate salt of isofagomine and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,863,453
App. No.
12/391,049
Granted
Jan 4, 2011
Kind
B2
Abstract

A novel tartaric acid salt of Isofagomine (Isofagomine tartrate) that can be used for the treatment of Gaucher disease is provided. The invention also provides a crystalline form of isofagomine tartrate, method for preparing the salt, a pharmaceutical composition containing the salt, and a method of treating Gaucher disease.

Claims (46)

1. A method for the preparation of isofagomine tartrate comprising:

(a) reacting isofagomine free base or its ionized form and L-(+)-tartaric acid in a molar ratio of 1:1 in a solvent; and

(b) isolating isofagomine tartrate.

2. The method of claim 1 , wherein at least one kilogram of isofagomine tartrate is isolated.

3. The method of claim 1 , wherein the solvent is an aqueous alcohol.

4. The method of claim 1 , wherein the solvent is an alcohol selected from methanol, ethanol, propanols, butanols, or mixtures thereof.

5. The method of claim 1 , wherein the solvent is ethanol.

6. The method of claim 1 , wherein step (b) includes crystallization of isofagomine tartrate.

7. The method of claim 6 , wherein 90% or more of isofagomine tartrate has a particle size of 1200 μm or less following crystallization of isofagomine tartrate.

8. The method of claim 6 , wherein crystallization of isofagomine tartrate comprises water and a secondary solvent.

9. The method of claim 8 , wherein the secondary solvent is a protic solvent.

10. The method of claim 9 , wherein the protic solvent is an alcohol.

11. A method for preparing high purity isofagomine tartrate on an industrial scale, the method comprising,

(a) reacting about 1 kg or more isofagomine free base or its ionized form and L-(+)-tartaric acid in a molar ratio of 1:1 in a solvent;

(b) obtaining a crude isofagomine tartrate;

(c) crystallizing the crude isofagomine tartrate using an aqueous solution; and

(d) isolating high purity isofagomine tartrate.

12. The method of claim 11 wherein the aqueous solution is water.

13. The method of claim 11 , wherein the aqueous solution is a mixture of water and an alcohol wherein water and the alcohol are used at the same time or with an interval of time.

14. The method of claim 11 , wherein high purity isofagomine tartrate is at least 84% pure by weight.

15. The method of claim 11 , wherein high purity isofagomine tartrate is at least 98% pure by weight.

16. The method of claim 11 , wherein high purity isofagomine tartrate is at least 99% pure by weight.

17. The method of claim 11 , wherein 90% or more of high purity isofagomine tartrate has a particle size of 1200 μm or less.

18. A method for the preparation of isofagomine tartrate comprising:

(a) reacting isofagomine free base or its ionized form and L-(+)-tartaric acid in a molar ratio of 2:1 to 1:1 in a solvent; and

(b) isolating isofagomine tartrate.

19. The method of claim 18 , wherein at least one kilogram of isofagomine tartrate is isolated.

20. The method of claim 18 , wherein the solvent is an aqueous alcohol.

21. The method of claim 18 , wherein the solvent is an alcohol selected from methanol, ethanol, propanols, butanols, or mixtures thereof.

22. The method of claim 18 , wherein the solvent is ethanol.

23. The method of claim 18 , wherein step (b) includes crystallization of isofagomine tartrate.

24. The method of claim 23 , wherein 90% or more of isofagomine tartrate has a particle size of 1200 μm or less following crystallization of isofagomine tartrate.

25. The method of claim 23 , wherein crystallization of isofagomine tartrate comprises water and a secondary solvent.

26. The method of claim 25 , wherein the secondary solvent is a protic solvent.

27. The method of claim 26 , wherein the protic solvent is an alcohol.

28. A method for preparing high purity isofagomine tartrate on an industrial scale, the method comprising,

(a) reacting about 1 kg or more isofagomine free base or its ionized form and L-(+)-tartaric acid in a molar ratio of 2:1 to 1:1 in a solvent;

(b) obtaining a crude isofagomine tartrate;

(c) crystallizing the crude isofagomine tartrate using an aqueous solution; and

(d) isolating high purity isofagomine tartrate.

29. The method of claim 28 wherein the aqueous solution is water.

30. The method of claim 28 , wherein the aqueous solution is a mixture of water and an alcohol wherein water and the alcohol are used at the same time or with an interval of time.

31. The method of claim 28 , wherein high purity isofagomine tartrate is at least 84% pure by weight.

32. The method of claim 28 , wherein high purity isofagomine tartrate is at least 98% pure by weight.

33. The method of claim 28 , wherein high purity isofagomine tartrate is at least 99% pure by weight.

34. The method of claim 28 , wherein 90% or more of high purity isofagomine tartrate has a particle size of 1200 μm or less.

Assignments (3)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →
SECURITY INTEREST Recorded Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →